Roche Q3 Revenue Tops Consensus at CHF16.13B, Guidance Confirmed
RHHBY sits 48% above its 52-week low of $40.07 on light trading volume (0.3× avg).
Summary
Roche beat on the top line with Q3 revenue of CHF16.13B ($19.61B), up 7% year over year and ahead of the CHF15.75B consensus. Pharma sales of $14.85B narrowly missed the $14.9B estimate, but diagnostics at $4.3B came in above expectations. All five top-selling drugs grew year over year, led by Ocrevus up 7% to CHF5.32B (~$6.5B). Management confirmed full-year guidance for mid-single-digit group sales growth and high-single-digit core EPS growth. The FDA decides on giredestrant for early-stage breast cancer by Nov. 30, with divarasib, fenebrutinib and sefaxersen approvals possible next year.
At the time of this announcement, RHHBY was trading at $59.48 on OTC in the Life Sciences sector, with a market capitalization of approximately $378.8B. The 52-week trading range was $40.07 to $60.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.